GlassScriptPhysician profile
Joshua D Price
NPI 1922661289
$2,470.51
in general payments reported to CMS, 2019-2025
23 companies · $912 in 2025
The $912 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.39 · 2023: $319 · 2024: $1,192 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.02 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $355.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $349.27 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $319.92 | 2023-2025 | Rexulti |
| Amgen INC. | $157.73 | 2023-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $131.62 | 2023-2024 | |
| Lilly USA, LLC | $125.36 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $73.63 | 2024-2025 | Trintellix |
| Ardelyx, INC. | $70.86 | 2025 | Ibsrela |
| Dexcom, INC. | $68.88 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $66.56 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.51 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $46.60 | 2024 | Trelegy Ellipta |
| Corcept Therapeutics | $40.72 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $39.79 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.01 | 2024-2025 | Jardiance |
| Atland Pharmaceuticals, LLC | $17.49 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Axsome Therapeutics, INC. | $17.41 | 2025 | Auvelity |
| Lundbeck LLC | $17.01 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $16.86 | 2023 | Vaxneuvance, M-M-R II, Proquad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.39 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $11.26 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.